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Abstract
Background: The peripheral blood (PB) monocyte pool contains osteoclast progenitors (OCPs), which contribute to
osteoresorption in inflammatory arthritides and are influenced by the cytokine and chemokine milieu. We aimed to
define the importance of chemokine signals for migration and activation of OCPs in rheumatoid arthritis (RA) and
psoriatic arthritis (PsA).
Methods: PB and, when applicable, synovial fluid (SF) samples were collected from 129 patients with RA, 53 patients
with PsA, and 110 control patients in parallel to clinical parameters of disease activity, autoantibody levels, and applied
therapy. Receptors for osteoclastogenic factors (CD115 and receptor activator of nuclear factor-κB [RANK]) and selected
chemokines (CC chemokine receptor 1 [CCR1], CCR2, CCR4, CXC chemokine receptor 3 [CXCR3], CXCR4) were determined
in an OCP-rich subpopulation (CD3−CD19−CD56−CD11b+CD14+) by flow cytometry. In parallel, levels of CC chemokine
ligand 2 (CCL2), CCL3, CCL4, CCL5, CXC chemokine ligand 9 (CXCL9), CXCL10, and CXCL12 were measured using
cytometric bead array or enzyme-linked immunosorbent assay. Sorted OCPs were stimulated in culture by macrophage
colony-stimulating factor and receptor activator of nuclear factor-κB ligand, and they were differentiated into mature
osteoclasts that resorb bone. Selected chemokines (CCL2, CCL5, CXCL10, and CXCL12) were tested for their
osteoclastogenic and chemotactic effects on circulatory OCPs in vitro.
Results: The OCP population was moderately enlarged among PB cells in RA and correlated with levels of tumor necrosis
factor-α (TNF-α), rheumatoid factor, CCL2, and CCL5. Compared with PB, the RANK+ subpopulation was expanded in SF
and correlated with the number of tender joints. Patients with PsA could be distinguished by increased RANK expression
rather than total OCP population. OCPs from patients with arthritis had higher expression of CCR1, CCR2, CCR4, CXCR3,
and CXCR4. In parallel, patients with RA had increased levels of CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10, with significant
elevation in SF vs PB for CXCL10. The subset expressing CXCR4 positively correlated with TNF-α, bone resorption marker, and
rheumatoid factor, and it was reduced in patients treated with disease-modifying antirheumatic drugs. The CCR4+ subset
showed a significant negative trend during anti-TNF treatment. CCL2, CCL5, and CXCL10 had similar osteoclastogenic effects,
with CCL5 showing the greatest chemotactic action on OCPs.
Conclusions: In our study, we identified distinct effects of selected chemokines on stimulation of OCP mobilization, tissue
homing, and maturation. Novel insights into migratory behaviors and functional properties of circulatory OCPs in response
to chemotactic signals could open ways to new therapeutic targets in RA.
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Background
Rheumatoid arthritis (RA) is a systemic inflammatory
disease manifesting predominantly as chronic affection
of multiple joints and osteodestruction, and involving
complex interactions between the immune system,
extracellular matrix, and bone cells [1]. Severe clinical
symptoms and the chronic course of the disease, under-
pinned by persistent inflammation, progressive joint de-
struction, and constant pain, require prolonged drug use
and result, despite treatment, in significant skeletal de-
formities and global disability [2]. With a prevalence of
around 1%, RA is one of the most common autoimmune
diseases in the human population and an important con-
tributor to public health burden, lower quality of life,
and reduced life expectancy. Although numerous studies
have been focused on the pathogenesis of RA, especially
disease etiology and onset, many questions remain un-
answered, specifically the underlying causes of perpetu-
ation of chronic inflammation and sustained renewal of
bone-resorbing cells [3, 4].
Osteoclasts (OCs) are multinucleated cells with the
unique ability to resorb bone. They develop by fusion of
hematopoietic precursors belonging to the monocyte/
macrophage lineage. OCs express receptors for two cru-
cial regulators of their differentiation and maturation:
macrophage colony-stimulating factor (M-CSF) and re-
ceptor activator of nuclear factor- κB ligand (RANKL,
CD254). The receptor for colony-stimulating factor-1
(cFms, CD115, M-CSF receptor) appears at early devel-
opmental stages of the myeloid lineage, whereas receptor
activator of nuclear factor-κB (RANK; CD265) is
expressed on committed osteoclast progenitors (OCPs)
and is crucial for OC survival and activation [5–7].
Physiologically, the main source of RANKL is osteoblast
lineage cells, but RANKL has also been shown to be
expressed by activated T lymphocytes, mature B lym-
phocytes, natural killer cells, and synoviocytes in inflam-
matory conditions. Furthermore, elevated levels of a
wide range of proinflammatory cytokines (interleukin-1
[IL-1], IL-6, IL-15, IL-17, IL-18, IL-21, IL-22, IL-23,
tumor necrosis factor-α [TNF-α]) and chemokines (CC
chemokine ligand 2 [CCL2], CCL3, CCL4, CCL5) act in
synergy with M-CSF/RANK signals to promote osteo-
clastogenesis [8, 9].
Because the life span of an individual OC is only a
couple of weeks, OCs must be constantly replenished to
sustain pathological bone resorption in the chronic
course of RA [3, 10, 11]. The peripheral blood (PB)
monocyte pool, originating from myeloid bone marrow
progenitors, contains 1–2% of cells capable of differenti-
ating in vitro into fully functional OCs in the presence
of M-CSF and RANKL [3, 12]. Owing to monocyte/
macrophage lineage heterogeneity and few consensual
specific markers of human OCPs, researchers have used
various monocyte markers in an attempt to better
characterize this osteoclastogenic subpopulation in PB.
On the basis of previous work of several groups, includ-
ing our own, lymphoid marker-negative (CD3, CD19,
CD56), CD11b and CD14 double-positive (DP) subpopu-
lation of peripheral blood mononuclear cells (PBMCs)
were identified as significantly OCP-enriched in patients
with RA and patients with psoriatic arthritis (PsA) [3].
Furthermore, it has been proposed that the erosive
phenotype of various forms of inflammatory arthritides
could be a result of the plasticity of these hematopoietic
monocytic progenitors, depending on the cytokine and
chemokine milieu in the bone marrow, circulation, and
synovium [13].
Chemokines are known to orchestrate the recruitment
of immune cells in RA and other inflammatory rheum-
atic diseases [14]. They may also be involved in OCP
trafficking because cells at various stages of OC lineage
express chemokine receptors (CC chemokine receptor 1
[CCR1] to CCR4, CXC chemokine receptor 3 [CXCR3],
CXCR4, or CX3C chemokine receptor 1) [15–18]. How-
ever, the contribution of chemotactic signals to homing
of OCPs and to their differentiation into mature OCs
has not been fully elucidated [3]. The aim of our present
study was to define the chemokine receptor profile of
peripheral OCPs specifically induced by arthritis as well
as the susceptibility of this cell subset to chemotactic
signals. Raised levels of chemokines and chemotactic
gradient between plasma and synovial fluid (SF) seem to
contribute not only to increased migration of OCPs but
also to their enhanced differentiation. Thus, immuno-
phenotyping of chemokine receptors as well as measure-
ment of respective chemokine levels may represent
useful parameters to assess arthritis severity, disease
progression, or response to therapy.
Methods
Patients
Patients with arthritis (RA, n = 129; PsA, n = 53) admit-
ted to Clinical Hospital Center “Sestre Milosrdnice”,
Clinical Hospital “Sveti Duh”, and Clinical Hospital
Center “Zagreb” were included in the study after ap-
proval was obtained from the ethics committees of those
institutions and of the University of Zagreb School of
Medicine, and informed consent was received from pa-
tients. Control subjects (CTRL; n = 110) were admitted
to the same institutions for noninflammatory etiology
and had no previous history of arthritic or autoimmune
diseases. A rheumatology specialist established the diag-
nosis of RA on the basis of American College of
Rheumatology 2010 criteria, whereas PsA was diagnosed
according to the Moll and Wright criteria [19, 20]. PB
samples were obtained from patients with RA and pa-
tients with PsA during routine clinical assessments and
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processed for analysis. The following data were also col-
lected from patients with arthritis: disease duration
(years), patient and physician assessment of disease ac-
tivity (visual analogue scale [VAS]), patient assessment
of pain and fatigue (VAS), tender joint count (TJC; out
of 28 joints), swollen joint count (SJC; out of 28 joints),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) level, Disease Activity Score in 28 joints (DAS28)
calculated with ESR, Clinical Disease Activity Index
(CDAI), treatment received (nonsteroidal anti-
inflammatory drugs [NSAIDs], disease-modifying antirheu-
matic drugs [DMARDs], corticosteroids, and/or biological
therapy), levels of rheumatoid factor (RF; determined by
turbidimetry), and anticitrullinated protein antibodies
(ACPA; determined by enzyme-linked immunosorbent
assay [ELISA]). For some analyses, patients with RA were
grouped on the basis of their DAS28 into severe (DAS28 >
5.1) and low/moderate cases (DAS28 2.6–5.1) [21–23]. A
cohort of patients with arthritis (n = 24) assigned for thera-
peutic arthrocentesis of the affected knee was included to
obtain SF samples. A small subset of patients (n = 9) sched-
uled for biological treatment with TNF inhibitors (etaner-
cept 50 mg weekly or adalimumab 40 mg every 2 weeks)
was followed by taking PB samples immediately before and
at 2, 4, and 6 months after onset of therapy.
Isolation of mononuclear cells
Blood samples were obtained between 9:30 and
11:30 a.m. PBMCs and plasma were separated from PB by
centrifugation (20 minutes at 600 × g) with Histopaque
(Sigma-Aldrich, St. Louis, MO, USA). Aspirated SF sam-
ples were separated by sequential centrifugation (5 minutes
at 100 × g) into acellular SF supernatants and SF-derived
cells (synovial fluid mononuclear cells [SFMCs]). Plasma
and SF samples were stored at −20 °C until a cytometric
bead array (CBA) or ELISA was performed, whereas
PBMCs and SFMCs were immediately used for flow cyto-
metric phenotyping, RNA extraction, cell sorting, osteo-
clastogenic cultures, and migration assays.
Flow cytometry
Phenotype characterization of OCPs from PB was per-
formed using an Invitrogen Attune flow cytometer
(Thermo Fisher Scientific, Waltham, MA, USA) and an-
alyzed using FlowJo software (FlowJo, LLC, Ashland,
OR, USA). Cells were counted in a hemocytometer by
trypan blue exclusion and labeled using a mix of com-
mercially available monoclonal antibodies against lymph-
oid lineage markers (anti-CD3 fluorescein isothiocyanate
[FITC] for T lymphocytes, anti-CD19 FITC for B
lymphocytes, and anti-CD56 FITC for natural killer cells),
myeloid lineage markers (anti-CD11b phycoerythrin [PE]-
cyanine 7 [Cy7] and anti-CD14 peridinin-chlorophyll-
cyanine 5.5), receptors for OC differentiation factors
(receptor for M-CSF [biotinylated anti-CD115], RANK
[anti-RANK PE]), and several chemokine receptors (anti-
CCR1 allophycocyanin [APC], anti-CCR2 PE, anti-CCR4
APC, anti-CXCR3 APC, anti-CXCR4 PE) (all from
eBioscience, San Diego, CA, USA). Suspensions were incu-
bated on ice for 40 minutes, followed by washing in staining
medium (PBS/2% FBS). As a second step (for biotinylated
anti-CD115), cells were stained with streptavidin coupled to
APC-eFluor 780 (Thermo Fisher Scientific) on ice for 40 -
minutes, followed by washing in staining medium, and
afterward they were resuspended in staining medium for
analysis. OCPs were defined as part of the monocytic sub-
population bearing the CD3−CD19−CD56−CD11b+CD14+
phenotype [3, 12]. The subpopulation was then analyzed for
expression of CD115 and RANK as well as for subsequent
chemokine receptor expression (CCR1, CCR2, CCR4,
CXCR3, and CXCR4). Gates for the analysis were defined
using unlabeled cells and "fluorescence minus one control".
Cell sorting
For fluorescence-activated cell sorting (FACS), PBMCs
of CTRL and RA samples were labeled using lymphoid
lineage markers (anti-CD3 FITC for T lymphocytes,
anti-CD19 FITC for B lymphocytes, anti-CD56 FITC for
natural killer cells) and myeloid lineage markers (anti-
CD11b APC and anti-CD14 PE-Cy7) and sorted using a
BD FACSAria I cell sorter (BD Biosciences, Franklin
Lakes, NJ, USA). Briefly, labeled cells were acquired at a
speed of approximately 5000 cells/second, and singlets
were delineated from the total cell population depicted
on forward vs side scatter plots, followed by plotting
lymphoid markers vs CD11b. Subsequently, lymphoid
marker-negative cells, intermediately positive for CD11b,
were gated for CD14 expression. A defined OCP popula-
tion (CD3−CD19−CD56−CD11b+CD14+) was sorted in
2-ml collection tubes containing α-minimal essential
medium (α-MEM)/20% FBS and used for osteoclasto-
genic cultures. Sorting purity was determined by
reanalysis of fractioned populations and was consistently
greater than 99%.
Osteoclast differentiation from sorted peripheral blood
mononuclear cells
Sorted OCPs were plated at a density of 4 × 104 cells
per well in 96-well plates in α-MEM/10% FBS. For
the first 3 days of cell culture, 60 ng/ml recombinant
human (rh)M-CSF (R&D Systems, Minneapolis, MN,
USA) was added to stimulate cell proliferation. The
next 8–11 days, the cell culture medium was supple-
mented with 100 ng/ml rhRANKL (R&D Systems)
and 30 ng/ml rhM-CSF to stimulate differentiation
into mature OCs. At days 11–13 of culture, OCs were
enumerated by staining for tartrate-resistant acid
phosphatase (TRAP).
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Migration assay
PBMCs were plated at a density of 10 × 104 per well in 48-
well plates in α-MEM/10% FBS and cultured overnight
with 35 ng/ml M-CSF. Nonadherent cells enriched in OCPs
were harvested for further analyses as previously described
[12]. Considering the heterogeneity of the PB monocyte/
macrophage lineage, the nonadherent fraction obtained
after short-term incubation was comprised of a mixture of
lymphocytes and immature monocytes. Lymphocytes were
mostly removed by subsequent media changes.
A portion of nonadherent cells was used in osteoclas-
togenic culture additionally treated with chemokines.
These cells were plated at a density of 2.5 × 104 cells per
well in 96-well plates in α-MEM/10% FBS supplemented
by 100 ng/ml rhRANKL and 30 ng/ml rhM-CSF, with
the addition of 40 ng/ml CCL2, 10 ng/ml CCL5, 20 ng/ml
CXC chemokine ligand 10 (CXCL10) or 50 ng/ml CXCL12
(PeproTech, Rocky Hill, NJ, USA). Assays were performed
on PB RA samples (n = 6–12 per chemokine treatment).
After 10–11 days, cells were stained with TRAP for OC
enumeration.
The remainder of nonadherent cells was used for the
Transwell culture system. The cells were plated at a
density of 5 × 104 cells per well in 48-well plates in α-
MEM/10% FBS with 100 ng/ml RANKL and 30 ng/
ml M-CSF. At day 2 of culture, adherent cells from each
sample were harvested and seeded into the upper cham-
bers of 24-well Costar Transwell plates (8.0-μm pore
size; Corning Inc., Corning, NY, USA) at a density of 104
cells/well in 100 μl of α-MEM/10% FBS, and the lower
chambers were filled with 40 ng/ml CCL2, 10 ng/ml
CCL5, 20 ng/ml CXCL10, or 50 ng/ml CXCL12 (Pepro-
Tech) in 500 μl of α-MEM/10% FBS. After 3-h incuba-
tion at 37 °C with 5% CO2, the upper surface of the
membrane was carefully washed with PBS, and the
remaining cells were removed with a cotton wool swab.
The cells that had migrated to the bottom side of the
Transwell membrane inserts were fixed with 4% parafor-
maldehyde and stained with 4′,6-diamidino-2-phenylin-
dole (DAPI). The migrated cells were counted (two wells
per group, five central fields per Transwell) at × 200
magnification using a fluorescence microscope (Axiovert
200; Carl Zeiss AG, Oberkochen, Germany).
The cells that had migrated through the Transwell
membrane to the lower chamber of the 24-well plate
were cultured for the next 8–9 days in α-MEM/10% FBS
supplemented with 100 ng/ml RANKL and 30 ng/ml M-
CSF. At the end of the culture period, plates were
stained for TRAP activity to determine the number of
differentiated OCs.
Detection of osteoclasts
The number of OCs differentiated from PBMCs or the
sorted OCP-enriched population was determined by
TRAP staining at the culture endpoint (days 10–13).
Osteoclastogenic cultures were grown as previously de-
scribed. Staining for TRAP was performed using a com-
mercially available set of chemicals according to the
manufacturer’s instructions (leukocyte acid phosphatase
kit; Sigma-Aldrich). OCs were identified and enumerated
as TRAP+ cells with two or more nuclei per cell at × 200
magnification by light microscopy using the Axiovert
200 fluorescence microscope.
Vitronectin receptor (VNR) expression and bone re-
sorption assays were performed in parallel with TRAP
staining to confirm the identity of OCs. For VNR detec-
tion, osteoclastogenic cultures were grown as previously
described. At culture days 14–16, cells were fixed in 4%
paraformaldehyde for 10 minutes and blocked for 30 mi-
nutes in 2% bovine serum albumin/PBS. Monoclonal bi-
otinylated CD51/CD61 (integrin αvβ3) antibody (1:80;
eBioscience) was incubated for 2 h at room temperature.
As a second-step reagent, streptavidin coupled to FITC
was incubated for 1 h at room temperature. Cell nuclei
were counterstained with DAPI. VNR expression was vi-
sualized at × 200 magnification using the Axiovert 200
fluorescence microscope.
For bone resorption assays, cells were plated over the
bovine cortical bone slices using the same osteoclasto-
genic culture conditions as previously described. At
culture days 16–18, cells were fixed in 4% paraformalde-
hyde for 10 minutes at room temperature. Following
TRAP staining using a commercially available set of che-
micals (leukocyte acid phosphatase kit; Sigma-Aldrich),
cells were removed from bone slices by sonication in
0.25 M NH4OH for 5 minutes. Bone slices were then
stained with 1% toluidine blue in 1% borax buffer for
2 minutes to visualize resorption pits at × 200 magnifica-
tion using an Axiovert 200 light microscope.
Cytometric bead array
CBA was performed using the Human Chemokine CBA
Kit (BD Biosciences, Sans Jose, CA, USA) to assess the
levels of CCL2, CCL3, CCL4, CCL5, CXCL9, and
CXCL10 in PB and SF samples. Plasma and SF superna-
tants were each diluted 1:4 using the supplied dilution
buffer and incubated with capture beads. Each capture
bead was coated with a capture antibody specific for
each soluble protein and could be identified by its dis-
tinct fluorescence signature in two fluorescence channels
on the flow cytometer (APC vs APC-Cy7). The samples
were then washed and incubated with the detection re-
agent. The concentration of the bound analyte was
determined by the intensity of the PE fluorescence, de-
pending on the amount of bound PE-conjugated anti-
bodies. After another washing step, complexes of capture
beads, analytes, and detection reagents were analyzed using
Invitrogen Attune flow cytometer. Concentrations of
Sucur et al. Arthritis Research & Therapy  (2017) 19:142 Page 4 of 16
chemokines were determined using FCAP Array version
3.0 software (BD Biosciences), based on standard curves
generated by data acquired from provided protein
standards.
Gene expression analysis by quantitative polymerase
chain reaction
Total RNA was extracted from PBMCs using Invitrogen
TRIzol reagent (Life Technologies, Carlsbad, CA, USA).
For polymerase chain reaction (PCR) amplification, 1 μg
of total RNA was converted to complementary DNA
(cDNA) by reverse transcriptase (Applied Biosystems,
Foster City, CA, USA) and stored at −20 °C until further
analysis. The amount of cDNA corresponding to 20 ng
of reverse-transcribed RNA was amplified by quantita-
tive polymerase chain reaction (qPCR) in an ABI Prism
7500 sequence detection system (Applied Biosystems).
Gene expression of CCL2 (hs00234140_m1), CCL3
(hs00234142_m1), CCL4 (hs99999148_m1), CCL5
(hs00982282_m1), and CXCL12 (hs02668440_m1) was
analyzed using commercially available TaqMan assays
(Applied Biosystems). Each reaction was performed in
duplicate in a 25-μl reaction volume. The relative quan-
tities were calculated using the standard curve designed
from six serial dilutions of the calibrator sample (CTRL
PBMCs). According to the standard curve, the relative
amounts of RNA for target genes were calculated as the
ratio of the quantity of the target gene normalized to
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) as
the endogenous control.
ELISA
Plasma concentrations of TNF-α (Quantikine HS ELISA
kit; R&D Systems), CXCL12 (Quantikine Immunoassay;
R&D Systems), and carboxy-terminal telopeptide of type
I collagen (CTX; Immunodiagnostic Systems, The
Boldons, UK), as well as SF concentrations of RANKL
(Quantikine Immunoassay; R&D Systems), were deter-
mined in accordance with the manufacturers’ instruc-
tions. Briefly, samples were incubated for 2–3 h at room
temperature on monoclonal antibody-precoated plates,
washed three times, and incubated for the next 2 h with
HRP-conjugated (CXCL12, RANKL) or alkaline
phosphatase-conjugated (TNF-α, CTX) specific anti-
bodies. After another three washes, the reactions were
visualized with substrate solution (tetramethylbenzidine)
(CXCL12, RANKL) or substrate and amplifier solutions
(nicotinamide adenine dinucleotide phosphate and amp-
lifier enzymes) (TNF-α, CTX) and then arrested with
hydrochloric or sulfuric acid, respectively. Optical dens-
ity was determined within 15 minutes on a microplate
reader (Bio-Rad Laboratories, Hercules, CA, USA) set to
an excitation wavelength of 450 nm (CXCL12, RANKL)
or 490 nm (TNF-α, CTX).
Statistical analysis
Data were presented as median with IQR for continuous
variables (including clinical scores, laboratory measures,
protein concentrations, cell numbers and frequencies) or
categorized for categorical variables (including sex,
DAS28 subgroup, and treatment). Statistical analysis of
the group differences was performed using a nonpara-
metric Mann-Whitney U test (for group-to-group com-
parisons) or the Kruskal-Wallis test followed by the
Mann-Whitney U test (for multiple comparisons).
Correlations were done using rank correlation and
Spearman’s coefficient ρ with 95% CI. Trend analysis
was performed on population frequencies during anti-
TNF therapy by using one-way analysis of variance
(ANOVA) with polynomial contrast type and testing for
linear trends. Multiple logistic regression analysis was
performed with the frequency of the PB OCP cells (CD3
−CD19−CD56−CD11b+CD14+) as the dependent variable.
Parameters were taken into consideration as independ-
ent variables if comparative analysis between CTRL and
RA values showed a significant difference. An extensive
search was then performed to see which three of the sig-
nificantly different independent variables resulted in
maximal adjusted R2 values, with pairwise exclusion of
missing values in the analysis. Statistical analyses were
performed using MedCalc for Windows version 9.4.2.0
software (MedCalc Software, Ostend, Belgium). For all
experiments, the α-level was set at 0.05.
Results
Patients with rheumatoid arthritis have highly active
disease with elevated inflammatory, osteoresorptive, and
autoimmune indicators
The demographic and clinical characteristics showed
that the majority of patients with RA included in the
study had a chronic course of active disease (median
DAS28 5.97; IQR 4.99–6.71) (Table 1) with multiple
joints affected and enhanced osteoresorption (median
CTX 0.38 [IQR 0.26–0.49] pg/ml in RA vs 0.28 [IQR
0.21–0.32] pg/ml in CTRL). The majority of patients
were seropositive with elevated inflammatory indicators
(ESR and CRP). Although patients were actively treated
(by NSAID, DMARD, glucocorticoid, or biologic ther-
apy), DAS28 and other clinical parameters (SJC, TJC,
CDAI) remained high, indicating poor regulation and
disease progression. Compared with CTRL subjects,
there were no differences between groups in terms of
age (median age 65 [IQR 48–68] years for CTRL vs 65
[IQR 51–74] years for RA) or sex (male/female ratio 21/
89 for CTRL vs 15/114 for RA).
To distinguish patients with RA on the basis of disease
activity and to set the frame for further comparisons
with laboratory and experimental data, we grouped dis-
ease parameters into variables reflecting the intensity of
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inflammation (CRP, ESR, TNF-α), joint destruction/bone
resorption (CTX, SJC/TJC, CDAI), and autoimmune re-
action (RF, ACPA), and we analyzed them with respect
to DAS28 categories (Fig. 1a). Levels of both TNF-α and
RF were significantly higher in severe cases (DAS28 >
5.1) than in CTRL cases and low/moderate cases
(DAS28 2.6–5.1). As a marker of bone resorption rate,
plasma CTX did not increase with disease severity,
which can be explained by a number of factors besides
RA that affect bone turnover (including patient age,
glucocorticoid use, and immobility) [24]. In addition,
with regard to treatment modalities, lower CTX values
were observed in DMARD-treated patients (Fig. 1b).
Circulating osteoclast progenitor cells from arthritic
patients have distinct functional and phenotypic features
On the basis of our previous findings [3, 12], PBMCs of
CTRL subjects and subjects with arthritis were analyzed
by FACS to determine the frequency of OCP populations
using the gating strategy presented in Fig. 2a. Briefly,
total PBMCs, depicted on forward vs side scatter plots,
were analyzed by plotting lymphoid markers vs CD11b.
Subsequently, a population of lymphoid-negative cells
(CD3−CD19−CD56−) expressing CD11b (CD11b+) was
confirmed by size and granularity to represent the
monocyte subpopulation and then further dissected for
the expression of CD14, CD115, and RANK. Lymphoid-
negative cells that highly expressed CD11b (CD11b++)
correspond to granulocytes, whereas lymphoid-positive
cells negative for CD11b correspond to lymphocytes. In
addition to PBMCs, SFMCs were analyzed using a simi-
lar gating strategy to determine specific systemic-to-
local differences between myeloid cell subsets.
We presumed that the inclusion of an RA cohort with a
significant proportion of highly active disease (sustained in-
flammation and joint destruction) would allow for a clearer
detection of distinct OCP subpopulations induced by arth-
ritis. Therefore, we first determined differences in PB of
CTRL and RA samples. The DP (CD11b+CD14+) subset of
PB monocytes was moderately expanded in patients with
RA compared with CTRL subjects (Fig. 2b). In RA, the pro-
portion of these cells was positively associated with plasma
levels of TNF-α and RF (Fig. 2c) but not with the level of
CTX (not shown). The DP PB population possesses osteo-
clastogenic potential because we were able to obtain fully
functional bone-resorbing OCs from sorted cells under
stimulation by M-CSF and RANKL (Fig. 2d). However, this
population generated numbers of differentiated TRAP+
OCs similar to those of CTRL subjects when seeded at the
same densities. In line with the latter finding, the frequency
of PB DP cells expressing corresponding receptors—CD115
(M-CSF receptor) and RANK (RANKL receptor)—was
comparable between CTRL subjects and patients with RA,
indicating similar responsiveness to the respective ligands
(Fig. 2b).
We further assessed differences between the circulatory
and synovial compartments of patients with RA and found
that the proportion of DP monocytes was comparable be-
tween PB and SF samples (Fig. 2b). Because it was not
feasible to obtain appropriate CTRL SF samples (owing to
Table 1 Demographic and clinical characteristics of patients with rheumatoid arthritis and psoriatic arthritis
RA PsA
Age, years 65 [51–74] 56 [44–74]
Sex, male/female 15/114 24/29
DAS28-ESR 5.97 [4.99–6.71] 5.50 [4.05–6.78]
DAS28-ESR 2.6–5.1/DAS28-ESR >5.1, % 25.0%/75.0% 41.8%/58.2%
CDAI 37.0 [24.0–44.1] 33.6 [14.0–52.1]
Disease duration, years 18.5 [9.0–29.0] 14.0 [8.0–30.0]
ESR, mm/h 27.5 [19.0–39.5] 14.5 [4.0–46.5]
CRP, mg/L 11.9 [4.8–24.5] 2.7 [0.7–29.1]
RF, IU/L 79.7 [15.0–239.0] N/A
ACPA, EU/L 68.7 [2.2–270.8] N/A
Tender joint count (out of 28) 15 [8–22] 17 [3–26]
Swollen joint count (out of 28) 7 [2–12] 6 [0–14]
Disease activity, cm, physician’s VAS assessment 7.0 [5.5–8.8] 6.4 [4.7–9.0]
Disease activity, cm, patient’s VAS assessment 7.0 [5.0–8.8] 6.9 [4.9–8.2]
Abbreviations: RA Rheumatoid arthritis, PsA Psoriatic arthritis, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, CDAI Clinical Disease Activity Index,
DAS28-ESR Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, VAS Visual analogue scale, RF Rheumatoid factor, ACPA Anticitrullinated
protein antibodies, EU ELISA units, N/A Not applicable
Values are presented as median with IQR, except DAS28 and sex categories
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the limited amount and low cellularity of SFs in healthy
synovial joints, as well as ethical unacceptability), we could
not compare the SFMC profile between CTRL subjects
and patients with RA. However, the proportion of DP
SFMCs in RA compared with DP PBMCs in CTRL sub-
jects was statistically higher, indicating a general increase
of the DP population associated with RA. Expression of
CD115 was lower in DP SFMCs than in the PBMC subset
of patients with arthritis, which can be explained by en-
hanced shedding of membrane receptors for proinflam-
matory mediators seen as a negative feedback loop in
inflamed tissues [25]. Nevertheless, the population of DP
monocytes expressing RANK, considered to represent
progenitors committed to OC lineage [3], was enlarged in
the synovial vs the circulatory compartment, showing a
positive correlation with TJC (Fig. 2c).
At this point, we also aimed to assess whether ob-
served changes were specifically associated with RA
compared with other forms of arthritis, as well as to
analyze another group of SFMC samples (not possible to
obtain from CTRL subjects). We included patients with
PsA with affected peripheral joints; they resemble RA by
having osteodestructive chronic inflammatory polyar-
thritis but are almost always seronegative with distinct
pathogenic and clinical features. In general, the fre-
quency of osteoclastogenic subpopulations followed a
pattern in patients with PsA similar to that in patients
with RA. Although the increase in proportion of PB DP
monocytes did not reach significance, the proportion of
these cells expressing RANK was significantly larger
than in CTRL subjects (Additional file 1: Figure S1a). In
our previous study, we indicated that the RANKL-
RANK axis may be specifically associated with PsA com-
pared with RA pathogenesis [12]. However, the level of
soluble RANKL was not significantly higher in PsA SF
than in RA SF (p = 0.355), possibly owing to the small
sample size (Additional file 1: Figure S1b).
Circulating osteoclast progenitors expressing chemokine
receptors are exposed to higher plasma chemokine levels
After a functional confirmation of osteoclastogenic poten-
tial for CD3−CD19−CD56−CD11b+CD14+ cells, but with-
out increases in the number of differentiated TRAP+ OCs
under M-CSF/RANKL stimulation in patients with arth-
ritis, we hypothesized that the enhanced OCP activity
might be caused by the complementary proinflammatory/
osteoclastogenic stimuli, namely chemokine signals [3].
Monocytes, which comprise OCPs, are known to ex-
press a variety of chemokine receptors, which, upon
ligand binding, initiate multiple cellular responses, in-
cluding migration, proliferation, differentiation, and
activation [26]. Proportions of DP subpopulations in
PB were higher for several chemokine receptors in
patients with RA (CCR1, CCR2, CCR4, CXCR4)
(Fig. 3a) and in patients with PsA (CCR1, CXCR4)
(Additional file 1: Figure S1c). In addition, receptor
expression for CCR1 and CXCR4 was significantly
higher in SFMCs than in PBMCs of patients with RA.
Only the monocyte expression of CCR4, with unique
ligands (CCL17 and CCL22) compared with CCR1 and
CCR2 [14], was significantly lower in SFMCs than in
PBMCs of patients with RA.
Upregulation of the distinct set of chemokine recep-
tors on OCPs suggested their high susceptibility to che-
mokine signals and prompted us to determine the
chemokine ligand profile in plasma and SF of patients
with RA. Using the flow cytometry-based, predesigned
Human Chemokine CBA Kit, we detected higher levels
of CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10 in
arthritis than in CTRL plasma (Fig. 3b). Moreover,
CXCL10 was significantly higher in SF than in plasma of
patients with RA, indicating a chemotactic gradient for
cell migration from the circulation to the synovial com-
partment. The increase of CCL2, CCL3 and CCL4 levels
in SF of patients with RA was significant compared with
Fig. 1 Elevated indicators of inflammatory activity, osteoresorption, and autoimmunity in rheumatoid arthritis (RA). a Plasma levels of tumor
necrosis factor-α (TNF-α), carboxy-terminal telopeptide of type I collagen (CTX), and rheumatoid factor (RF) in control subjects (CTRL) and patients
with RA, categorized by Disease Activity Score in 28 joints (DAS28) as low/moderate RA (DAS28 2.6–5.1) and severe RA (DAS28 > 5.1). b Plasma
CTX levels with regard to disease-modifying antirheumatic drug (DMARD) therapy in patients with RA. Values are presented as medians (middle
lines), with boxes representing IQR, whiskers representing 1.5 times the IQR, and squares or circles representing outliers. Group-to-group comparisons
were performed using a nonparametric Mann-Whitney U test, and p values <0.05 are shown. N/A Not applicable
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Fig. 2 Expanded osteoclast progenitor (OCP) population correlates with indicators of disease activity in rheumatoid arthritis (RA). a Peripheral
blood mononuclear cells were analyzed by flow cytometry using the gating strategy for OCPs as nonlymphoid (CD3−CD19−CD56−) cells double-positive
for monocyte markers CD11b and CD14, and they were further assessed for the expression of macrophage colony-stimulating factor receptor (CD115) and
receptor activator of nuclear factor-κB (RANK). b Proportion of OCPs, and CD115+ and RANK+ subsets in peripheral blood of control (CTRL) subjects and
patients with RA, as well as RA synovial fluid (SF) samples. Gates for the analysis were defined using unlabeled cells and "fluorescence minus one control". c
Association of the proportion of circulating OCPs with plasma levels of rheumatoid factor (RF) and tumor necrosis factor-α (TNF-α), as well as association of
the proportion of RANK+ OCPs with tender joint count (TJC). d Quantification, morphology, and bone-resorbing activity of osteoclasts (OCs) differentiated
from sorted peripheral blood OCPs in RA and CTRL samples. Osteoclastogenic potential of circulating OCPs was evaluated in vitro by stimulating sorted
CD3−CD19−CD56−CD11b+CD14+ cells with macrophage colony-stimulating factor (30 ng/ml) and RANK ligand (100 ng/ml). Multinuclear cells positive for
tartrate-resistant acid phosphatase (TRAP) were counted as mature OCs. Bone-resorbing activity was confirmed for sorted cells by pit formation assay under
the same culture conditions. TRAP-stained mature OCs and bovine cortical bone slices from CTRL and RA cultures were scanned using light microscopy
at × 200 magnification. Red arrows indicate bone resortion pits, formed by active mature osteoclasts. Values are presented as medians (middle lines), with
boxes representing IQR, whiskers representing 1.5 times the IQR, and squares or circles representing outliers. Group-to-group comparisons were performed
using a nonparametric Mann-Whitney U test, whereas correlations were done using rank correlation and Spearman’s coefficient ρ. p Values <0.05
are shown
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CTRL plasma, considered as the basal level. However,
the difference was not significant compared with RA
plasma, probably owing to the small number of SF sam-
ples and high variability (with part of the measurements
below the detection limit of the CBA). Additionally,
CXCL12 was measured by ELISA, with no difference
found between groups (Fig. 3c). Indirectly, we confirmed
that PBMCs were not the major source of chemokines
by analyzing their gene expression using qPCR (Add-
itional file 2: Figure S2). With the exception of CCL5,
which was abundant at protein and gene expression
levels, chemokines were barely detectable by qPCR,
and there were no differences between groups, sug-
gesting that they are produced by cells other than
PBMCs and egress into the circulation to exert
chemotactic effects.
Fig. 3 Increased expression of chemokine receptors by osteoclast progenitors and higher chemokine levels in plasma and synovial fluid (SF) of
patients with rheumatoid arthritis (RA). a Flow cytometric analysis of chemokine receptors on osteoclast progenitors (CD3−CD19−CD56−CD11b+CD14+) in
peripheral blood of control subjects (CTRL) and patients with rheumatoid arthritis (RA), as well as in RA SF samples. Gates for the analysis were defined
using unlabeled cells and "fluorescence minus one control". b Levels of chemokine ligands in peripheral blood of CTRL subjects and patients with RA, as
well as in RA SF samples, measured by a flow cytometry-based, predesigned cytometric bead array. c Levels of CXC chemokine ligand 12 (CXCL12)
in peripheral blood of CTRL subjects and patients with RA, as well as in RA SF, measured by enzyme-linked immunosorbent assay. Values
are presented as medians (middle lines), with boxes representing IQR, whiskers representing 1.5 times the IQR, and squares or circles representing
outliers. Group-to-group comparisons were performed using a nonparametric Mann-Whitney U test, and p values <0.05 are shown. CCR CC chemokine
receptor, CXCR CXC chemokine receptor, CCL CC chemokine ligand
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Chemokine receptor/ligand levels are associated with
clinical variables and indicate biological significance for
disease pathogenesis and progression
To this point, our data confirmed increased chemokine
levels in patients with RA, which may be responsible for
enhanced migration of OCPs expressing appropriate re-
ceptors. Therefore, we further assessed the association
between the frequency of OCPs and their chemokine re-
ceptor expression with the level of proinflammatory me-
diators and clinical parameters of the disease. The
proportion of PB DP monocytes was positively associ-
ated with plasma levels of CCL2 and CCL5 (Fig. 4a), and
both ligands were positively associated with TNF-α (ρ =
0.549, p < 0.001 for CCL2; ρ = 0.554, p < 0.001 for CCL5).
In addition, the proportion of DP subsets expressing
CCR1 and CCR4 was significantly associated with
plasma levels of corresponding chemokine ligands (ρ =
0.477, p = 0.006 for CCR1 with CCL3; ρ = 0.655, p <
0.001 for CCR4 with CCL2; ρ = 0.420, p = 0.010 for
CCR4 with CCL3). Besides findings in patients with RA,
the proportion of PB DP monocytes was positively associ-
ated with ESR in patients with PsA (ρ = 0.822, p < 0.001).
Among analyzed chemokine receptors, the DP subset ex-
pressing CXCR4 showed the most significant associations
with inflammatory indicators and disease activity, including
TNF-α concentration, duration of arthritis, autoantibody
levels, and bone resorption (Fig. 4b). Moreover, the propor-
tion of the DP subset expressing CXCR4 was significantly
lower in patients treated with DMARD (Fig. 4c), whom we
showed to also have a lower bone resorption rate (Fig. 1b).
Therefore, we concluded that the highly osteoclastogenic
DP population of PBMCs, especially the subset expressing
CXCR4, may be used as an indicator of disease activity and
response to therapy.
Finally, we assessed the contribution of analyzed data
to the frequency of PB DP cells and found that multiple
logistic regression was able to explain 79% of the
variability of the DP subpopulation frequency (ad-
justed R2 = 0.790) from CCL5, CXCL10, and CXCR4
values. These variables significantly predicted the fre-
quency of DP monocytes (p < 0.001), adding to the
prediction in the following order: CCL5 (β = 0.527, p
< 0.0001), CXCL10 (β = 0.522, p < 0.0001), and CXCR4
(β = 0.284, p = 0.015).
Chemokine receptor expression is significantly affected
by anti-TNF therapy, indicating involvement of chemo-
kine signals in anti-TNF response
Therapeutic targeting of proinflammatory mediators has
been approved for arthritis treatment to suppress in-
flammatory responses as well as subsequent local and
systemic bone loss. Our preliminary data on PsA sam-
ples (n = 4) showed a positive association between the
proportion of PB DP monocytes and DAS28, as well as
Fig. 4 Association of peripheral blood osteoclast progenitor (OCP)
frequency and proportions of subsets expressing chemokine receptors
with chemokine levels and indicators of disease activity. a Association of
peripheral blood OCP frequency (CD3−CD19−CD56−CD11b+CD14+) with
plasma concentration of CC chemokine ligands (CCL2, CCL5) in control
subjects (CTRL) and patients with rheumatoid arthritis (RA). b Association
of CXC chemokine receptor 4 (CXCR4) expression in OCPs with arthritis
duration, plasma levels of tumor necrosis factor-α (TNF-α), carboxy-
terminal telopeptide of type I collagen (CTX), and rheumatoid factor (RF).
c Proportions of CXCR4+ OCPs in patients with or without treatment
with disease-modifying antirheumatic drugs (DMARDs). Association
was established using rank correlation, and Spearman’s coefficient ρ
and p values are shown for total data, including both CTRL and RA,
whereas group trend lines are shown separately as dashed lines
for CTRL and solid lines for RA. Group-to-group comparisons
were performed using a nonparametric Mann-Whitney U test,
and p values <0.05 are shown. Values are presented as medians
(middle lines), with boxes representing IQR, whiskers representing
1.5 times the IQR, and squares or circles representing outliers
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reduction of both variables along with the anti-TNF
treatment in two of four patients [3].
In this study, the small cohort of patients (RA, n =
4; PsA, n = 5) receiving anti-TNF therapy was
followed to 6 months after the initial application.
PBMCs were analyzed as previously described for pa-
tients with RA and patients with PsA (Fig. 2a). The
total DP population was not suppressed by the treat-
ment, and neither were the subsets expressing recep-
tors for crucial osteoclastogenic factors: CD115 and
RANK (Fig. 5a). In general, individual values were
highly variable even at the starting point, which may
be due to the fact that included patients were already
in the chronic phase of the disease, having had arth-
ritis for more than 10 years and having previously
been treated with different combinations of NSAIDs,
glucocorticoids, and DMARDs. However, the subpop-
ulation of DP monocytes expressing CCR4 showed
significant dynamic changes in response to anti-TNF
therapy, exhibiting a significant negative trend during
the anti-TNF treatment in patients with RA and pa-
tients with PsA, offering the possibility of using it as
an indicator of a good therapeutic response (Fig. 5b).
We observed elevated plasma levels of major CCR4
ligands (CCL2, CCL3, CCL5) and a significant posi-
tive correlation of CCR4 expression with CCL2 and
CCL3 in patients with RA. Therefore, the downregu-
lation of CCR4 may be important to reducing the
susceptibility of OCPs to the chemokine gradient.
Functional in vitro confirmation of direct osteoclastogenic
and chemotactic effect of chemokines on circulating
osteoclast progenitors
Finally, we functionally tested the effects of chemokines
on circulatory monocytes in vitro for their chemotactic
and osteoclastogenic properties. PBMCs from individual
samples of RA patients were first stimulated by M-CSF
overnight, then nonadherent cells were harvested and
split into two groups: One was grown further in osteo-
clastogenic culture conditions under chemokine treat-
ment to assess direct osteoclastogenic effects, and the
other was plated in a Transwell culture system to deter-
mine chemotaxis of OCPs toward the chemokine gradi-
ent (Fig. 6a). The latter migration assay was further
analyzed for the number of attracted cells and for their
osteoclastogenic potential. For these experiments, we se-
lected CCL2, CCL5, and CXCL10 on the basis of recep-
tor/ligand profiling in PB samples (Fig. 3). Besides
Fig. 5 Alteration of chemokine receptor expression on circulatory osteoclast progenitors (OCPs) in follow-up of anti-TNF therapy. a Proportion of
OCPs (CD3−CD19−CD56−CD11b+CD14+) and their subsets expressing macrophage colony-stimulating factor receptor (CD115) and receptor activator
of nuclear factor-κB (RANK) in peripheral blood of patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) before (0) and 2, 4,
and 6 months after induction of anti-TNF therapy (etanercept 50 mg weekly or adalimumab 40 mg every 2 weeks). b Subsets of OCPs expressing
chemokine receptors with regard to duration of anti-TNF therapy in patients with RA and patients with PsA. Values are presented as median
with IQR for each time point. Analysis for linear trend was performed using one-way analysis of variance with polynomial contrast type. p Values <0.05
are shown. CCR CC chemokine receptor, CXCR CXC chemokine receptor
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higher CCR1, CCR2, and CCR4 (that bind CCL2 and
CCL5), we found that CXCR3 (receptor for CXCL10)
was also increased on OCPs in patients with RA (median
43.1% [IQR 33.3–54.2] in CTRL vs 61.5% [IQR 53.3–
69.2] in RA, p = 0.009). CCL2 was taken as representa-
tive of a chemokine involved only in monocyte recruit-
ment, whereas CXCL10 was taken as a chemokine that
nonselectively attracts both myeloid and lymphoid line-
ages. In addition, we tested CCL5, which was found to
be elevated in plasma but lower in SF, indicating its role
in systemic activation rather than in joint-specific
homing [27]. On the basis of CXCR4 expression (Fig. 3a),
CXCL12 was also selected for in vitro migration assays,
but in our culture conditions, the effects on osteoclasto-
genesis or chemotaxis were marginal or not observed,
respectively (median ratio 1.31 [IQR 1.21–1.38] for the
number of OCs in CXCL12-treated vs nontreated cul-
tures, p = 0.106; ratio 0.97 [IQR 0.77–1.56] for the num-
ber of migrated cells in CXCL12-treated vs nontreated
cultures, p = 1.000).
We expected great susceptibility of PB monocytes to
chemokine signals in RA, considering their higher
Fig. 6 Stimulatory osteoclastogenic and chemotactic effects of chemokines on circulating osteoclast progenitors in rheumatoid arthritis. a
Schematic presentation of experimental design. We evaluated chemokine osteoclastogenic and chemotactic effects on nonadherent cells
harvested after overnight culturing of peripheral blood mononuclear cells (PBMCs) with 35 ng/ml macrophage colony-stimulating factor (M-CSF).
For the osteoclastogenic assay, cells were further cultured with M-CSF (30 ng/ml) and receptor activator of nuclear factor-κB ligand (RANKL;
100 ng/ml), supplemented by CC chemokine ligand 2 (CCL2; 40 ng/ml), CCL5 (10 ng/ml), or CXC chemokine ligand 10 (CXCL10; 20 ng/ml). Multi-
nuclear cells positive for tartrate-resistant acid phosphatase (TRAP) were counted as mature osteoclasts (OCs). For the migration assay, cells were
first cultured for 2 days with M-CSF and RANKL, then transferred to a Transwell culture system, applying chemokine gradient (CCL2, CCL5, or
CXCL10). Cells migrating through the Transwell membrane were enumerated by 4′,6-diamidino-2-phenylindole (DAPI) staining. Migrated cells
were further differentiated by M-CSF and RANKL and assessed for the number of TRAP+ OCs. b Relative expression of chemokine receptors on
osteoclast progenitors (CD3−CD19−CD56−CD11b+CD14+) in peripheral blood samples of patients with rheumatoid arthritis compared with the
median value of control (healthy) subjects, as measured by flow cytometry. c Relative number of TRAP+ OCs generated by chemokine treatment
compared with respective untreated osteoclastogenic culture (no chemokine). d Relative number of cells migrating by chemokine gradient
through Transwell membrane compared with respective untreated migration assay (no chemokine). e Relative number of TRAP+ OCs generated
from cells that had migrated to the lower chamber compared with respective untreated osteoclastogenic culture (no chemokine). Values are pre-
sented as medians (middle lines), with boxes representing IQR, whiskers representing 1.5 times the IQR, and squares or circles representing outliers. Red
horizontal lines represent the relative value of the respective control. Group-to-group comparisons were performed using a nonparametric Mann-
Whitney U test, and p values <0.05 are shown. CCR CC chemokine receptor, CXCR CXC chemokine receptor
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expression of chemokine receptors than CTRL (Fig. 6b).
In general, CCL2, CCL5, and CXCL10 showed measur-
able osteoclastogenic as well as chemotactic effects. In
the direct osteoclastogenic effect, all tested chemokines
showed comparable potential (doses were optimized in
accordance with the median effective dose provided by
the manufacturer) and generated similar numbers of
TRAP+ OCs (Fig. 6c). In addition, the identity of differ-
entiated OCs was further confirmed by expression of
VNR and bone-resorbing activity (Additional file 3: Fig-
ure S3). Interestingly, CCL5 showed the greatest chemo-
tactic effects among tested chemokines by attracting the
highest number of cells in the migration assay (Fig. 6d).
In addition, these migrated cells possessed greater osteo-
clastogenic potential when stimulated by RANKL and
M-CSF than untreated cells and cells attracted to CCL2
and CXCL10 gradient (Fig. 6e). These results imply that
chemokine signals not only stimulate chemotaxis of
OCPs but also act synergistically with RANKL and M-
CSF to enhance their differentiation into mature OCs.
Discussion
Our study provides evidence of the importance of che-
mokine signals to complement the canonical M-CSF/
RANKL-mediated OC differentiation pathway by stimu-
lation of OCP migration and maturation. Although gen-
etic experiments in mice and primary human cell
cultures have helped define the regulation of OC differ-
entiation under physiological conditions, alternative
pathways of OC stimulation, especially in patients with
inflammatory conditions, are not yet clear. The complex
environment that orchestrates pathological osteoresorp-
tion involves a variety of mediators and several cell
types, both as sources and targets of these secreted fac-
tors [28]. Our study revealed specific roles for several
chemokines. Namely, CCL2, CCL5, and CXCL10 exhibit
a similar magnitude of direct osteoclastogenic action,
whereas when tested in vitro, CCL5 has the strongest
chemotactic effect on OCPs. However, CCL5 was lower
in SF than in plasma of patients with RA in vivo, sug-
gesting its significance for the systemic mobilization of
myeloid cells rather than their accumulation in the syn-
ovial compartment.
The susceptibility of OCPs to chemotactic signals and
the increased production of respective chemokines cre-
ate optimal conditions for their enhanced homing not
only to affected joints but also at the systemic level [29].
Immunophenotyping of PB cells from patients with RA
showed a moderate expansion of the total monocyte
pool (CD11b+CD14+), with high osteoclastogenic activ-
ity. Furthermore, frequencies of OCP subpopulations ex-
pressing chemokine receptors (CCR1, CCR2, CCR4,
CXCR3, CXCR4) were significantly increased. These
subpopulations, specifically CD3−CD19−CD56−CD11b
+CD14+CXCR4+ cells, were positively associated with
the indicators of disease severity (i.e., levels of TNF-α,
chemokines, autoantibodies, and CTX) and further ex-
panded in the synovial compartment. Moreover, the re-
duction of the CXCR4+ subset in patients treated with
DMARDs pointed to the potential application of its fre-
quency as an indicator of a good therapeutic response.
Inactivation of CXCR4 has been shown to effectively
ameliorate symptoms in murine collagen-induced arth-
ritis, a mouse model of RA [30]. Although CXCL12, an
exclusive CXCR4 ligand, has also been implicated in the
pathogenesis of several skeletal disorders, including RA
[31], we found no difference in CXCL12 levels between
plasma and SF of patients with RA, nor did we find a
difference compared with the CTRL group. In our in
vitro assay, CXCL12 did not show a significant osteo-
clastogenic or chemotactic effect. Studies in which re-
searchers observed a chemotactic effect of CXCL12 were
focused mainly on bone marrow and not on PB OCPs
[32, 33]. Thus, in the systemic circulation, involvement
of the CXCL12-CXCR4 axis in RA seems to depend on
receptor rather than ligand modulation.
In contrast to CXCL12, several tested chemokines
(CCL2, CCL4, CXCL10) were elevated in plasma and
enriched in SF, indicating that they are produced by cells
within the synovial compartment, from whence they spill
over into the circulation proportionately to the intensity
of the disease [34]. Although aware that a comparison
between arthritic and CTRL SF would provide better in-
sights into the changes of the chemokine ligand/receptor
profile associated with arthritis, we were unable to ob-
tain appropriate CTRL SF, owing to the limited amount
and low cellularity in healthy synovial joints. In addition,
arthrocentesis in patients with arthritis was performed
for therapeutic evacuation of SF, whereas SF aspiration
from healthy subjects has no ethical justification, consid-
ering the pain and discomfort involved as well as the risk
of articular tissue damage, infection, and joint dysfunc-
tion [35]. On the basis of increases in proportions of
CCR1+ and CCR2+ DP subsets, we propose that the
CCR1- and CCR2-mediated chemotaxis (by CCL2 and
CCL4 ligands) is important for joint-specific recruitment
of OCPs. CCR2, expressed in lymphoid and myeloid
cells, is important for the recruitment of cells from
several lineages, including monocytes, into the joints
[27, 36, 37]. In an in vitro study, Lebre et al. suggested
that CCR1 blockade might be effective in inhibiting the
migration of monocytes toward the synovial compart-
ment in RA [27]. Among DP SFMCs, the CCR4+ popu-
lation was not enriched, indicating that CCR4 is not
crucial for accumulation of monocytes in arthritic joints,
as opposed to its importance for T lymphocytes [38].
However, circulatory CCR4+ OCPs were significantly
suppressed during anti-TNF therapy. There are several
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functional links between TNF-α and chemokine effects
that can be modulated by TNF blockade, including
TNF-mediated vascular activation that promotes
leukocyte adhesion and chemotaxis [39], as well as TNF-
induced chemokine secretion by resident and infiltrating
inflammatory cells [27]. The dynamic changes of the
chemokine receptor profile by anti-TNF treatment ob-
served in our study may reduce OCP susceptibility to
chemokine signals and offer a powerful tool to control
disease progression.
In addition to providing chemotactic signals, chemo-
kines may act additively to M-CSF/RANKL stimulation
to enhance OC differentiation. In our in vitro condi-
tions, we observed an increased number of differentiated
bone-resorbing OCs under CCL2, CCL5, and CXCL10
treatment. Studies on isolated human PB monocytes
using different culture systems pointed to a direct
osteoclastogenic effect of several chemokines, includ-
ing CCL2 and CCL5, through autocrine and paracrine
loops [12, 40, 41]. Besides a direct osteoclastogenic
effect, chemokines may be involved in ACPA-
mediated OC differentiation [42]. These noncanonical
pathways of OC differentiation are specifically import-
ant in inflammatory settings, when chemokines as
well as proinflammatory cytokines (TNF-α and IL-1)
substitute RANKL and M-CSF to augment OC differenti-
ation [43]. A RANKL surplus has not been observed in
some animal models of inflammation-induced bone loss,
explaining why blocking of the canonical M-CSF/
RANKL-mediated osteoclastogenic pathway does not
achieve clinical benefit [13]. Negative feedback mecha-
nisms initiated during excessive inflammation may cause
refractoriness to M-CSF by ectodomain shedding of
CD115 on early human OCPs [25]. This is in line with our
observation of significantly reduced CD115 membrane ex-
pression in SF-derived monocytes from patients with RA
as well as patients with PsA. However, reduced M-CSF ex-
pression was not associated with downregulation of
RANK expression, suggesting that OC differentiation pro-
ceeded despite negative feedback, which was possibly
overridden by the excess of other proinflammatory osteo-
clastogenic signals.
Chemotactic signaling is thought to be important in
the pathogenesis of RA, and various chemokines, along
with their respective receptors, have been implicated in
leukocyte ingress into inflamed synovia [8]. In spite of
tremendous efforts to identify immunological abnormal-
ities in RA, a clear association between specific immune
cell populations and RA disease activity measures has
not been identified, especially for innate immune cells.
The majority of studies have dealt with cells involved in
adaptive immunity, especially CD4+ T lymphocytes [44].
Substantial expression of chemokine receptors on PB
monocytes, and more specifically on OCPs, may be
particularly important for RA pathogenesis because che-
mokines initiate several cellular responses crucial for the
destructive effects on bone tissue. Although much is
known regarding chemokine ligand and receptor profiles
in patients with RA, blocking therapy generally did not
yield the expected results, thus indicating that more data
are required regarding cell- and disease-specific details.
The relevant myeloid subpopulations might be more
heterogeneous than currently appreciated, with unique
markers of OCP subpopulations in various forms of
arthritis [13, 28]. By immunophenotyping the chemokine
receptor profile on OCPs, and by assessing the in vivo
chemokine milieu as well as its in vitro effects, we were
able to add to the understanding of the complex inflam-
matory network present in patients with RA.
Conclusions
Our results reveal the role of chemokines as potent pro-
inflammatory, chemotactic, and osteoclastogenic factors
that may be important for systemic stimulation of OCPs,
as well as their increased migration, subsequent tissue
homing, and in situ maturation. In addition, we identi-
fied arthritis-associated OCP subsets expressing chemo-
kine receptors, which are therefore susceptible to the
chemokine gradient, explaining local as well as general-
ized bone loss seen in RA. Novel insights with regard to
the migratory behavior and functional properties of
OCPs in response to chemokine signals could open a
doorway to new therapeutic targets in RA.
Additional files
Additional file 1: Figure S1. Increased frequency of osteoclast
progenitor cells and subsets expressing chemokine receptors in
peripheral blood and synovial fluid samples of patients with RA and
PsA. a Proportion of OCPs, subsets expressing macrophage colony-
stimulating factor receptor (CD115) and RANK in peripheral blood of
CTRL subjects and patients with arthritis, and SF samples (SF RA, SF
PsA), assessed by flow cytometry. b Concentrations of soluble RANKL
in SF of arthritic patients, measured by ELISA. c Chemokine receptor
expression on OCPs in peripheral blood of CTRL subjects and patients with
arthritis, and SF of patients with arthritis, assessed by flow cytometry. Values
are presented as medians (middle line), with boxes representing IQR, whiskers
representing 1.5 times the IQR, and squares or circles representing outliers.
Group-to-group comparisons were performed using a nonparametric
Mann-Whitney U test, and p values <0.05 are shown for comparisons made
between PsA and other groups. Previously shown p values for comparisons
between RA and CTRL groups (Figs. 2 and 3) are not shown again for the
sake of visual clarity. (TIF 1768 kb)
Additional file 2: Figure S2. Low level of chemokine gene expression
in PBMCs of patients with RA. qPCR analysis of the expression of
chemokine genes in PBMCs of CTRL patients and patients with RA,
presented as RNA RQ. Values are presented as medians (middle line),
with boxes representing IQR, whiskers representing 1.5 times the IQR
and squares or circles representing outliers. Group-to-group comparisons
were performed using a nonparametric Mann-Whitney U test, p values
<0.05 are shown. (TIF 987 kb)
Additional file 3: Figure S3. OCs differentiated from PBMCs exhibit
OC-specific phenotype and bone-resorbing activity. The number of
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multinucleated cells expressing TRAP was used for quantification of
differentiated OCs under stimulation by M-CSF and RANKL. To further
confirm the identity of OCs, parallel cultures were performed and stained
for VNR expression. Functional bone-resorbing activity of differentiated OCs
was confirmed by pit formation assays using bovine cortical bone slices
under the same culture conditions. Presented are representative images of
osteoclastogenic cultures of PBMCs from control subjects and patients with
RA. In addition, cultures from patients with RA stimulated with CCL5
(10 ng/ml) are shown to confirm the osteoclastogenic effect of CCL5.
Red arrows indicate bone resortion pits, formed by active mature os-
teoclasts. TRAP-stained mature OCs and bovine cortical bone slices were
imaged under light microscopy at × 200 magnification. VNR-expressing ma-
ture OCs were imaged using a fluorescence microscope at × 200 mag-
nification. (TIF 4477 kb)
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